For decades, the biopharmaceutical industry has relied on three foundational quality attributes to evaluate therapeutic products:
Identity. Purity. Potency.
These pillars have served as the framework for ensuring products are what they claim to be, are free from unacceptable contaminants, and perform their intended biological function.
As cell and gene therapies continue to transform medicine, however, a critical question is emerging:
Are these three pillars alone sufficient to characterize advanced therapies?
Increasingly, the answer appears to be no.
The unique biology and manufacturing complexity of cell and gene therapies have introduced new risks that are not fully addressed by traditional quality paradigms. As a result, genomic integrity is rapidly emerging as a foundational quality attribute that deserves consideration alongside identity, purity, and potency.
In other words, genomic integrity represents the fourth pillar of quality.
The Traditional Three Pillars
Every therapeutic product is expected to demonstrate:
Identity
Confirmation that the product is the correct biological entity and possesses the intended characteristics.
Purity
Evidence that unwanted contaminants, impurities, or unintended materials are controlled within acceptable limits.
Potency
Demonstration that the product performs its intended biological function and is capable of producing the desired therapeutic effect.
These quality attributes remain essential. However, they do not necessarily provide insight into the structural integrity of the genome itself.
A product can meet specifications for identity, purity, and potency while still harboring genomic abnormalities that may influence safety, manufacturability, consistency, or long-term performance.
Why Advanced Therapies Are Different
Unlike traditional biologics, cell and gene therapies often involve direct manipulation of genetic material.
Gene editing, viral vector manufacturing, cell expansion, reprogramming, transduction, and manufacturing scale-up can all introduce or select for genomic changes.
These changes may include:
- Emergence of polyploid populations
- Chromosomal rearrangements
- Translocations
- Inversions
- Deletions
- Duplications
- Complex structural variants
- Clonal expansion of abnormal cell populations
Some genomic events may have little or no biological consequence. Others may influence cellular behavior, persistence, efficacy, or safety.
The challenge is that many of these events cannot be inferred from identity, purity, or potency testing alone.
The Limitations of Traditional Testing
Historically, developers have relied on a combination of analytical methods to evaluate genomic safety and product quality.
These may include:
- Diagnostic Karyotyping
- Targeted sequencing
- Integration site analysis
- Vector characterization assays
- Molecular marker assessments
Each of these methods provides valuable and often essential information.
The challenge is that most analytical approaches are designed to answer specific questions regarding genomic structure, function, or sequence composition. As a result, no single method provides a complete view of genomic integrity.
Diagnostic karyotyping evaluates large chromosomal abnormalities in a limited cell population, normally consisting of 20 cells, but can miss important subpopulations, smaller structural changes and rare events. Targeted sequencing focuses on predefined genomic regions and may overlook unexpected abnormalities elsewhere in the genome. Integration site analysis can identify insertion locations but may provide limited information regarding broader chromosomal consequences surrounding those events.
As therapies become increasingly sophisticated, relying on a single testing approach may create blind spots that leave important genomic risks undetected.
Genomic Integrity as a Critical Quality Attribute
The concept of genomic integrity extends beyond detecting abnormalities.
It asks a broader question:
How confident are we that the genomic architecture of the product remains stable, predictable, and consistent throughout development and manufacturing?
Genomic integrity is not synonymous with genomic safety. Rather, it provides a framework for understanding, monitoring, and managing genomic changes that may influence product quality, consistency, and risk.
When viewed through this lens, genomic integrity begins to resemble other established quality attributes.
Like purity, it can be monitored.
Like potency, it can change over time.
Like identity, it contributes to defining the product itself.
Most importantly, genomic integrity can influence patient outcomes.
This makes a compelling case for treating genomic integrity as a Critical Quality Attribute (CQA) rather than a specialized research metric.
Why the Fourth Pillar Matters
The consequences of genomic instability may not become apparent until late in development, or even after patient treatment.
Monitoring genomic integrity provides a means to evaluate the impact of these changes and may help explain sources of product variability that are not apparent through traditional release testing alone.
By incorporating genomic integrity assessments earlier and more consistently, developers gain the ability to:
Detect Emerging Risks Earlier
Early detection provides opportunities to investigate and mitigate abnormalities before they become development setbacks.
Strengthen Process Development
Manufacturing changes, scale-up activities, raw material modifications, and process optimization efforts can all affect genomic stability. Monitoring genomic integrity provides a means to evaluate those impacts and may explain unaccounted for process variability.
Improve Comparability Assessments
As products evolve throughout development, genomic integrity data can help demonstrate consistency between manufacturing processes and product versions.
Enhance Regulatory Readiness
Regulators increasingly expect comprehensive characterization of advanced therapies. Robust genomic integrity data can support risk assessments and strengthen regulatory submissions.
Increase Confidence in Patient Safety
Ultimately, the purpose of genomic integrity testing is to improve confidence that patients are receiving therapies that have been thoroughly characterized and understood.
The Importance of In Vivo Therapies
The need for genomic integrity assessment becomes even more significant for in vivo therapies.
With ex vivo therapies, developers often have the opportunity to test engineered cells before they are administered to patients.
In vivo therapies offer no such opportunity.
Once a viral vector or genetic payload is delivered to the patient, the intervention cannot be recalled or recharacterized.
Developers must establish confidence in product design, manufacturing controls, and genomic characterization before treatment occurs.
This reality elevates genomic integrity from a scientific consideration to a patient safety imperative.
From Quality Control to Quality Strategy
Historically, genomic testing has often been treated as a point-in-time characterization activity.
The future is likely different.
As the field matures, genomic integrity may become an ongoing quality strategy integrated throughout the product lifecycle.
As genomic integrity datasets continue to grow, benchmarking against historical datasets, reference materials, and manufacturing experience may become increasingly important. Understanding whether a genomic profile falls within an expected range may prove just as valuable as detecting individual abnormalities.
Instead of asking whether a product passed a genomic assessment at a single point in time, developers may increasingly ask:
- Has genomic stability been maintained throughout development?
- Has process optimization introduced new risks?
- Has manufacturing scale-up altered the genomic profile?
- Can we demonstrate consistency over time?
These questions are fundamentally quality questions.
The Future of Quality in Cell and Gene Therapy
Identity, purity, and potency will remain essential pillars of therapeutic development.
But advanced therapies require a more comprehensive understanding of product quality than ever before.
As the industry continues to evolve, genomic integrity has the potential to become a defining quality attribute that complements and strengthens the traditional framework.
Companies that embrace genomic integrity as part of their quality strategy today may be the ones best positioned to navigate tomorrow's scientific, regulatory, and manufacturing challenges.
Because in advanced therapies, quality is no longer defined solely by what a product is, how pure it is, or how well it works.
It is also defined by the integrity, stability, and consistency of the genome that underlies it.
As advanced therapies continue to evolve, genomic integrity may become one of the most important measures of whether a product is truly understood.
And that may make genomic integrity the fourth pillar of quality.